ECOG-logo
SOAPP

   NCT00303914

patient-doctor
  HOME COMMITTEES BACKGROUND SOAPP DATA SETS PUBLICATIONS Collaboration FAQ  
     
  ABOUT ECOG | RESOURCES | CONTACT | FEEDBACK  

Q: Can anyone use the MDASI to see how they are doing in their practice or institution? Is permission or a fee required?

A: To use the MDASI in a publication or clinical research trial, you must obtain permission and you must agree to comply with the copyright. Fees may apply (see below).

  • To obtain permission, fill out an order form, which is available at http://www3.mdanderson.org/depts/symptomresearch/. The MDASI will be e-mailed to you as a PDF file within 7 to 10 business days
  • If your request is urgent, please contact MD Anderson at: symptomresearch@mdanderson.org or at the address or phone number below to make special arrangements:
    • The Department of Symptom Research
      Attn: Assessment Tools
      The University of Texas MD Anderson Cancer Center
      1515 Holcombe Boulevard, Unit 1450
      Houston, Texas 77030
      713-745-3805
  • The fee structure is as follows:
    • Non-funded academic research and individual clinical practice: free of charge
    • Funded academic research: $300 per project for the first language version, $150 per each additional language version within a project
    • Commercial research: $1,000 per project for the first language version, $500 per each additional language version within a project
  • If applicable, an invoice will be e-mailed to you within 10 days. Please reference the invoice number on your payment. Include on the memo line "MD Anderson Assessment Tool Distribution."

For more information, please visit the M.D. Anderson Web site or read Assessing Symptom Distress in Cancer Patients by Dr Cleeland.

Notice of Copyright
The M. D. Anderson Symptom Inventory (MDASI) copyright is held by The University of Texas MD Anderson Cancer Center and administered by the MDASI's developer, Charles S. Cleeland, PhD. The copyright applies to the MDASI, its modules and all its derivatives in any language. The MDASI and its modules may not be used or reproduced without permission from the copyright administrator or his designee. Fees for use may apply (see above).

Neither the MDASI nor any of its modules may be modified or translated into another language without the express written consent of the copyright administrator or his designee. Failure to comply may result in legal action. Contact us via e-mail at symptomresearch@mdanderson.org or at the address shown above to obtain permission to alter or translate the instrument.

Q: Are there funds available for secondary concepts utilizing the E2Z02 SOAPP data?

A: Although there are no ECOG grants or funds available to promote further secondary concepts, investigators may use the E2Z02 SOAPP dataset for funding applications of their own. For example: An investigator outside of ECOG had written an R21 to fund efforts in analyzing aspects of this dataset.

Q: Are there any SOAPP publications available?

A: The first E2Z02 (SOAPP) article was recently published by the Journal of Clinical Oncology: Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012 Apr 16;[Epub ahead of print]. doi:10.1200/JCO.2011.39.2381.

Q: Why were more than 2310 patients enrolled to the SOAPP protocol (E2Z02), far exceeding the target accrual?

A: The anticipated accrual goal was 2310 patients and their physicians. We planned to accrue 2/3 of the patients (n = 1540) from primary CCOPS, providing good representation from general community practices. To assure adequate power to describe patients treated in disease-specific academic clinics, the goal was to accrue 1/3 of the patients (n = 770) from ECOG's main academic institutions. Assuming follow-up on 70% of patients, this would have given good power to detect changes in MDASI scores in reasonable subgroups. Approval to enroll patients was granted to qualifying CCOPs in 100-patient blocs. During the course of the study, deviations from the original plan occurred as a result of the desire to assure adequate enrollment from minority institutions along with the tremendous enthusiasm for the study among CCOP institutions. This enthusiasm caused a swell of enrollment after termination was announced, and resulted in significant accrual beyond the target.

Q: Were patients on the E2Z02 (SOAPP) study followed for survival?

A: Patients enrolled on the SOAPP study were not followed for survival. Therefore, no survival data are available.

Q: Were any biospecimens collected and banked on the SOAPP study?

A: No specimens were collected for banking.

  SPOTLIGHT
Watch Dr Fisch's ABC News highlight of Cancer Patients' Pain Remains Undertreated by clicking here

1st SOAPP Article Published
Click here to access first E2Z02 (SOAPP) article published by the Journal of Clinical Oncology: Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012 Apr 16;[Epub ahead of print].

ASCO 2012
Six SOAPP abstracts were accepted at the ASCO Annual Meeting 2012:

Cancer Type Abstract No. Lead Author
Health Services Research Poster 6076 F. Zhao
Health Services Research Poster 6080 C. Ritchie
Patient and Survivor Care Clin Sci Symp 9016 J. Manola
Patient and Survivor Care Poster 9099 X. S. Wang
Patient and Survivor Care Poster 9106 T. R. Mendoza
Patient and Survivor Care Poster 9112 M. J. Fisch

Please click on the Publications tab to view these abstracts, or click here for more information on the 2012 ASCO meeting and accepted abstracts.

MASCC 2012
Three abstracts were accepted for the MASCC (Multinational Association of Supportive Care in Cancer) meeting in New York City on June 27-29. One abstract is on determinants of driving (Victor Chang), another on concordance related to comorbidity (Elizabeth Kvale), and a third on pain change according to baseline severity (Fengmin Zhao).
©2012, Eastern Cooperative Oncology Group